Skip to main content
Article thumbnail
Location of Repository

Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day : a systematic review and economic evaluation

By J Hislop, Z Quayyum, A Elders, C Fraser, D Jenkinson, G Mowatt, P Sharma, L Vale and R Petty

Abstract

Peer reviewedPublisher PD

Topics: R Medicine, Chief Scientist Office (CSO), CSO--HERU2, CSO--HSRU1, R
Year: 2011
DOI identifier: 10.3310/hta15250
OAI identifier: oai:aura.abdn.ac.uk:2164/2123
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/2164/212... (external link)
  • http://dx.doi.org/10.3310/hta1... (external link)
  • Suggested articles

    Citations

    1. (2011). (imatinib or gleevec or glivec or sti571 or sti 571) S12 S10 and S11 S13 TX (sunitinib or sutent or su11248 or su 11248)
    2. (2005). [Gastrointestinal stromal tumors. Actual diagnosis and treatment.] Rev Med Chir Soc Med Nat Iasi
    3. [Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib]. Rofo 2003;175:791–8. Kale SS. A case and literature review of complicated gastrointestinal stromal tumors.
    4. (2005). [Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case.] Suppl Tumori
    5. [Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate.]
    6. (2011). 0matinib 600 to sunitinib 4 *9:table ^ith imatinib 600 7+ ^ith sunitinib 7+ ^ith initial treatment imatinib 600 *9:table ^ith sunitinib
    7. (2011). 10.3310/hta15250 121. de Mestier P, des Guetz G. Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics.
    8. (2011). 10.3310/hta15250 18. The Cochrane Collaboration. The Cochrane Collaboration’s tool for assessing risk of bias. In: The Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. London: The Cochrane Collaboration;
    9. (2011). 10.3310/hta15250 Appendix 10 Search strategies for review of economic analysis studies, costeffectiveness analysis MEDLINE
    10. (2011). 10.3310/hta15250 Appendix 13 Alternative best supportive care survival estimates Source Year Definition of population for which survival outcome is given No. in sample Follow-up time Median OS Percentage surviving Conlon18
    11. (2011). 10.3310/hta15250 Appendix 6 List of included studies Blanke B2222 study Primary reference
    12. (2011). 10.3310/hta15250 Diagnostic Technologies and Screening Panel Members Chair, Professor Lindsay Wilson Turnbull, Scientific Director of the Centre for Magnetic Resonance Investigations and YCR Professor of Radiology,
    13. (2011). 10.3310/hta15250 Interventions Description of intervention (e.g. dose, number of times taken per day , care provided etc)
    14. (2011). 10.3310/hta15250 licensed for treatment of GIST in 2002 and is now the standard first-line treatment for ‘locally advanced, inoperable patients and metastatic patients’ with GIST.11 The
    15. (2011). 10.3310/hta15250 with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+).
    16. 106 Appendix 5 Perol D. Does interruption of imatinib in responding GIST patients after one year of treatment influence the secondary resistance to IM after its reintroduction? J Clin Oncol 2008;26(Suppl. 5):Abstract 10556.
    17. 18F FDG PET/CT in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    18. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
    19. (2011). 5 0matinib 800 to sunitinib 4 *9:table ^ith imatinib 800 7+ ^ith sunitinib 7+ ^ith initial treatment imatinib 800 *9:table ^ith sunitinib
    20. (2002). A guideline for the management of gastrointestinal stromal tumour (GIST). Sarcoma
    21. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
    22. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
    23. (2005). A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM.
    24. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors with C-Kit exon 11 mutation.
    25. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected highrisk localized GIST.
    26. A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. doi
    27. (2006). A phase III trial of sunitinib in GIST patients following failure of imatinib mesylate: updated trial results. Ann Oncol
    28. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
    29. A preliminary evaluation of the potential role of FDG-PET to assess response to Glivec (TM) in gastrointestinal stromal tumours (GISTs).
    30. A prospective, multicenter, phase 2 study of imatinib mesylate in Korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    31. (2009). A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol
    32. (2011). A report of three patients treated with immunocell therapy with imatinib mesylate.
    33. (2008). A sunitinib exposure-effect based meta-analysis of treatment-related adverse events (TRAEs) in patients with metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Clin Pharmacol Ther
    34. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.
    35. (2003). Abs Pap Am Chem Soc
    36. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
    37. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISGAGITG phase III trial.
    38. Acquired resistance to imatinib in gastrointestinal stromal tumor (GIST) occurs through secondary gene mutation.
    39. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    40. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    41. adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
    42. (2005). Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the US Intergroup Phase II trial ACOSOG Z9000.
    43. Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor.
    44. Adjuvant post-surgery therapy with imatinib in intermediate or high-risk gastrointestinal stromal tumour (GIST) patients: interim analysis from a single centre comparison study.
    45. Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk.
    46. Advancing treatment of gastrointestinal stromal tumors (GIST).
    47. Aggressive surgical resection for the management of hepatic metastases from gastrointestinal stromal tumours: a single centre experience.
    48. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
    49. An exposure-response-based metaanalysis of the efficacy of sunitinib in patients with gastrointestinal stromal tumor.
    50. (2008). Analysis of genomic imbalances in imatinib-resistant, progressive gastrointestinal stromal tumors by array comparative genomic hybridization (aCGH). Cell Oncol
    51. (2011). and TS=monte carlo # 13 #5 and TS=conjoint analys*
    52. (2005). Apoptotic and anti-vascular activity of imatinib in GIST patients.
    53. Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate.
    54. (2007). Assessment of plasma levels of soluble KIT (sKIT) as a potential surrogate marker for TTP in patients (pts) with advanced gastrointestinal stromal tumor (GIST) treated with sunitinib.
    55. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    56. Bayesian methods in meta-analysis and evidence synthesis.
    57. (1985). Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis
    58. Biology of gastrointestinal stromal tumors.
    59. (2002). C-KIT and GIST: rational use of Glivec in gastrointestinal stromal tumors. Ann Pathol
    60. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
    61. (2009). Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res
    62. (2009). Centre for Reviews and Dissemination (CRD). Systematic reviews: CRD’s guidance for undertaking systematic reviews in health care.
    63. (2009). Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res
    64. (2008). Clin Oncol 2009;39:105–10. Seddon
    65. Clinical activity and tolerability of continuous daily dosing of sunitinib in patients with advanced GIST.
    66. (2006). Clinical benefit of continuous daily dosing of sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Ann Oncol
    67. (2007). Clinical experience with perioperative sunitinib and extensive resection of imatinib-resistant metastatic GIST. Ann Oncol
    68. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
    69. Clinical presentation and treatment of gastrointestinal stromal tumors. Tumori 2006;92:279–84. De
    70. Clinical response to imatinib mesylate in recurrent and metastaic gastrointestinal stromal tumors.
    71. (1990). Clinical study on gastrointestinal stromal tumors (GIST) in Iceland,
    72. (2006). Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum
    73. (2007). Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res
    74. (2008). Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches.
    75. Conjunctival hemorrhagic events associated with imatinib mesylate.
    76. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in patients with advanced GIST.
    77. (2007). Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing.
    78. Continuous versus interruption of imatinib in responding patients.
    79. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group.
    80. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    81. Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the RTOG phase II clinical trial S-0132.
    82. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    83. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: doi
    84. (2006). Correlation of receptor tyrosine kinase (RTK) activity and apoptosis with response to sunitinib treatment in patients with gastrointestinal stromal tumor (GIST).
    85. (2011). Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM)
    86. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
    87. (2007). CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
    88. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET finding.
    89. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
    90. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate).
    91. (2008). Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs
    92. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST.
    93. Diagnosis and conservative treatment of gastrointestinal stromal tumors (GIST).] Deutsche Medizinische Wochenschrift 2004;129:1808–10. Cabebe E, Wakelee H. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
    94. diagnosis and therapeutic options in gastrointestinal stromal tumours.
    95. (2007). Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Med Sci Monitor
    96. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): an analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
    97. Do patients with initially resected metastatic GIST benefit from ‘adjuvant’ imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial.
    98. Does tumor mutational status correlate with clinical response to imatinib?
    99. Don’t interrupt imatinib in GIST patients.
    100. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST – phase III Sarcoma Group Study S0033. J Clin Oncol 2004;22(Suppl. 14):Abstract 9005. EORTC-ISG-AGITG (62005) study Primary reference Zalcberg
    101. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG.
    102. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    103. (2009). ECCO 15: European Cancer Conference,
    104. Effect of angio-echography with a second-generation contrast agent to assess tumor response to imatinib treatment in patients with advanced gastrointestinal stromal tumor (GIST): comparison with computerized tomography (CT).
    105. (2011). Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.
    106. Effectiveness of imatinib in GIST continues for the long-term.
    107. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning.
    108. Efficacy and safety of adjuvant post-surgical therapy with imatinib.
    109. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    110. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
    111. Efficacy and safety of sunitinib in patients with gastrointestinal stromal tumour resistant or intolerant of prior imatinib therapy: results from a worldwide treatment-use study. Onkologie 2008;31(Suppl. 1):77-Abstract OP130.
    112. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
    113. (2007). Efficacy of sunitinib in patients with gastrointestinal stromal tumor (GIST): an exposure-response based meta-analysis. Mol Cancer Ther
    114. Efficacy, safety, pharmacokinetic and pharmacodynamic analysis of sunitinib (Su) adminstered on a continuous daily dosing (CDD) schedule in patients with advanced GIST.
    115. (2011). Elevations in creatine kinase occur frequently in patients treated with imatinib mesylate (Gleevec). Arthritis Rheum 2008;58:25. Helwick C. Focus on hematology. Good survival with adjuvant imatinib for high-risk GIST.
    116. Erythropoietin for anemia treatment of patients with GIST receiving imatinib.
    117. Evaluation of gastrointestinal stromal tumor patients and imatinib therapy. doi
    118. (2004). Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum
    119. (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med
    120. FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor.
    121. (2005). FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate.
    122. FDG-PET to measure response to targeted therapy: the example of gastrointestinal stromal tumor and imatinib mesylate (Gleevec).
    123. Focus on hematology, Gleevec postsurgery sharply reduces GIST recurrences.
    124. (2006). Focus on hematology. Long-term imatinib recommended for metastatic GIST even after complete resection, French study shows. Oncol News Int
    125. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
    126. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    127. (2011). Gastric stromal tumors: histopathological, clinical and therapeutical aspects.
    128. (1987). Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg
    129. Gastrointestinal stromal tumor (GIST): single center experience of prolonged treatment with imatinib. doi
    130. Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era.
    131. (2001). Gastrointestinal stromal tumor workshop. Hum Pathol
    132. (2006). Gastrointestinal stromal tumor: epidemiology and outcome study in 40 cases.
    133. (2006). Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors. Anal Quant Cytol Histol
    134. (2008). Gastrointestinal stromal tumors – frequency, malignancy, and new prognostic factors: the experience of a single institution. Path Res Pract
    135. (2007). Gastrointestinal stromal tumors (GIST) and laparoscopic resection. Surg Endosc
    136. (2004). Gastrointestinal stromal tumors (GIST): a model for moleculebased diagnosis and treatment of solid tumors.
    137. Gastrointestinal stromal tumors (GIST): a paradigm of successful targeted therapy of solid tumors.
    138. (2007). Gastrointestinal stromal tumors (GIST): clinical aspects. Rev Esp Enferm Dig doi
    139. (2011). Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with long-term follow-up.
    140. (2006). Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with long-term follow-up. Mod Pathol
    141. Gastrointestinal stromal tumors (GISTs): analysis of 20 cases.
    142. Gastrointestinal stromal tumors and leiomyosarcomas.
    143. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
    144. Gastrointestinal stromal tumors of the anorectum – a special entity: GISTs of the anorectum.
    145. Gastrointestinal stromal tumors: biology and treatment.
    146. (2000). Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol
    147. (2007). Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol
    148. (2006). Gastrointestinal stromal tumors: experience in 49 patients. Clin Translat Oncol
    149. (2006). Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med
    150. (2009). Gastrointestinal stromal tumors: surgical treatment. Gastroenterologia y Hepatologia Continuada
    151. (2005). Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer
    152. (2009). Gastrointestinal stromal tumour in the elderly. Crit Rev Oncol Hematol
    153. Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases.
    154. (2009). Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol
    155. (2006). Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment. Langenbecks Arch Surg doi
    156. Getting the gist of GIST… gastrointestinal stromal tumor.
    157. Giant malignant gastrointestinal stromal tumors (> 10cm): recurrent factors and effect
    158. Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571.
    159. GIST adjuvant therapy – some answers and more questions.
    160. (2008). GIST with deletion of TYR568 and TYR570 of kit have similar prognosis and response to imatinib as those with DELWK557–558, but are mainly extra-gastric. Ann Oncol
    161. (2005). GIST: molecular tests predict response to imatinib. Oncology Times
    162. GIST: risk of recurrence and dissemination.
    163. (2002). Good results continue for Gleevec for GIST… Metastatic gastrointestinal stromal tumors. Oncology Times
    164. Hematological and nonhematological toxicities of imatinib mesylate in patients with chronic myeloid leukemia and gastrointestinal stromal tumor.
    165. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin N Am 2009;23:115. Intervention not relevant (n = 15) Awasthi
    166. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
    167. (2005). Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy.
    168. IGFBP3 induces apoptosis in gastrointestinal stromal tumors but does not mediate response to imatinib mesylate.
    169. (2005). Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST).
    170. (2002). Imatinib (Gleevec) an active agent for gastrointestinal stromal tumours (GIST), but not for other soft tissue sarcoma (STS) subtypes not characterized for KIT and PGDF-R expression: results of EORTC phase II studies. Proc Am Soc Clin Oncol
    171. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
    172. (2002). Imatinib for gastrointestinal stromal tumours.
    173. Imatinib for the treatment of life-threatening gastrointestinal cancer.
    174. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    175. Imatinib in gastrointestinal stromal tumors.
    176. Imatinib in the treatment of gastrointestinal stromal tumour.
    177. Imatinib may enable complete resection in previously unresectable or metastatic GIST.
    178. Imatinib mesylate (IM) in locally advanced and metastatic gastrointestinal stromal tumours (GISTs): Cambridge GIST study group experience.
    179. (2005). Imatinib mesylate activates IGFBP3 expression in gastrointestinal stromal tumors. Clin Cancer Res
    180. (2007). Imatinib mesylate as first line therapy in patients with gastrointestinal stromal tumour (GIST). An experience from India. Ann Oncol
    181. (2005). Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the intergroup EORTC/ ISG/AGITG randomized trial in 946 patients. doi
    182. Imatinib mesylate in treatment of advanced gastrointestinal stromal tumours.
    183. (2006). Imatinib mesylate response in gastrointestinal stromal tumors: experience of Cerrahpasa Medical Faculty. Ann Oncol
    184. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
    185. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. Oncology 2007;73:324–7. 400 mg/day imatinib dose only (n
    186. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. doi
    187. Imatinib response linked to variations in drug exposure.
    188. (2006). Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Curr Oncol Rep
    189. (2008). Impact of demographic and clinical factors on the pharmacokinetics (PK) of sunitinib in patients and healthy volunteers. Clin Pharmacol Ther
    190. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.
    191. Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST).
    192. Inflammatory response affects the pharmacokinetics (PK) and pharmacodynamics (PD) of imatinib and CGP 74588 in patients with advanced gastrointestinal sarcoma (GIST).
    193. (2008). Initiation of sunitinib treatment 24 hours following a final dose of imatinib in patients with advanced gastrointestinal stromal tumor: safety and tolerability. Ann Oncol
    194. Interest of Dopplerultrasonography with perfusion software and contrast injection to early evaluation and detection of secondary resistence of gastrointestinal stromal tumors treated with imatinib.
    195. Interruption of imatinib in GIST patients with advanced disease after one year of treatment.
    196. (2007). Investigation of soluble KIT as a potential surrogate marker for TTP in sunitinib-treated patients with GIST. Ann Oncol
    197. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial?
    198. Is there a role for surgery in patients with ‘unresectable’ cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
    199. Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.
    200. (2007). Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Ann Surg Oncol
    201. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. doi
    202. (2005). KIT hyperactivation in imatinib-resistant GIST: implications for salvage therapies.
    203. (2011). KIT mutations and sunitinib resistance in gastrointestinal stromal tumors (GISTs).
    204. (2009). Le Cesne A. Imatinib in the treatment of solid tumours. Target Oncol doi
    205. Long term progression-free survval correlates with KIT/PDGFR.
    206. (2007). Long-term effects of imatinib therapy and impact of surgery on patients (pts) with CD117(+) gastrointestinal stromal tumours (GIST) without early progression on imatinib.
    207. (2008). Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours. Langenbecks Arch Surg
    208. Long-term results from a randomized phase II trial of standard versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
    209. (2008). Long-term survival in a phase III trial of sunitinib in imatinib-resistant/intolerant gastrointestinal stromal tumor with novel statistical analysis to account for crossover. Ann Oncol
    210. (2008). Management of gastrointestinal stromal tumors: a single center experience in the pre-imatinib era.
    211. Management of gastrointestinal stromal tumours in the imatinib era: a surgeon’s perspective.
    212. MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate.
    213. (2009). Medical Association and Royal Pharmaceutical Society of Great Britain.
    214. (2006). Medicines Consortium. Sunitinib 50 mg capsule (Sutent) No.275/06.
    215. Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST): a meta-analysis based on 1640 patients.
    216. (2008). Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomark Prevent
    217. (2008). Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomarkers Prev
    218. Molecular biomarkers and imatinib efficacy in metastatic gastrointestinal stromal tumors.
    219. (2009). Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res
    220. (2002). Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: a quantitative analysis. Radiology
    221. Mutations in gastrointestinal stromal tumors: a population-based study from Northern Norway.
    222. (2009). National Institute for Health and Clinical Excellence (NICE). Gastrointestinal stromal tumours – sunitinib: final appraisal determination.
    223. (2008). National Institute for Health and Clinical Excellence (NICE). NICE guide to the methods of technology appraisal.
    224. (2008). National Institute for Health and Clinical Excellence (NICE). Single technology appraisal of sunitinib for the treatment of gastrointestinal stromal tumours.
    225. (2004). National Institute for Health and Clinical Excellence (NICE). TA86 Gastro-intestinal stromal tumours (GIST) – imatinib: quick reference guide.
    226. (2009). Natural killer cell IFNgamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res
    227. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST): update of the NCCN clinical practice guidelines.
    228. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST).
    229. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs placebo (PL) in advanced GIST after imatinib failure.
    230. Nucl Med Mol Imaging 2004;31(Suppl. 2):335. Fiore
    231. (2006). Observation results of patients with gastrointestinal stromal tumors (GIST) subjected to surgical treatment: commentary. Pol Przegl Chir
    232. Ocular side-effects associated with imatinib mesylate [Gleevec (R)].
    233. (2006). One institutional experience with imatinib mesylate in the treatment of gastrointestinal stromal tumors. Ann Oncol
    234. (2007). Organisation ECCO 14: European Cancer Conference,
    235. Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST).
    236. Outcome following aggressive surgical therapy for gastrointestinal stromal tumor.
    237. Outcome following surgical therapy for gastrointestinal stromal tumors.
    238. (2006). Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: four year follow-up of a phase II randomized trial [abstract].
    239. (2006). Outcome of metastatic GIST in the era before imatinib mesylate. Ann Surg Oncol
    240. (2007). Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol
    241. (2009). Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD): an international, intergroup study of the EORTC,
    242. Outcome of patients with advanced GIST achieving a complete remission.
    243. (2007). Outcome of patients with locally advanced GIST receiving imatinib mesylate in a prospective trial. Ann Oncol
    244. Outcomes for patients with advanced GIST.
    245. Outcomes not reported separately for patients with
    246. Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy.
    247. (2011). Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res
    248. (2005). Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate (SU11248).
    249. Pattern of progression and its impact on outcome in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a retrospective multicenter long-term follow-up study.
    250. (2005). Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
    251. PDGFRA activating mutations in gastrointestinal stromal tumors.
    252. (2006). PET imaging demonstrates two patterns of response in GIST patients benefiting from long-term sunitinib therapy. Ann Oncol
    253. (2005). Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST.
    254. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    255. (2004). Phase II clinical study of STI571 in Japanese (Jpn) patients (pts) with malignant gastrointestinal stromal tumors
    256. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model.
    257. (2009). Phase II trial of adjuvant imatinib mesylate after resection of localized primary high risk GIST.
    258. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
    259. (2008). Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol
    260. (2008). Phase II, openlabel study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res
    261. (2002). Phase III dose-randomized study of imatinib mesylate (Gleevec,
    262. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase:
    263. Population pharmacokinetic (PK)-pharmacodynamic (PD) meta-analysis of sunitinib malate (SU11248) efficacy and tolerability endpoints in gastrointestinal stromal tumor (GIST), metastatic renal cell carcinoma (MRCC) and solid tumor patients.
    264. Pre-operative imatinib for recurrent, metastatic and locally advanced gastrointestinal tumours (GIST). Ann Oncol 2008;19(Suppl. 6):72.
    265. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
    266. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    267. (2004). Preliminary results of the phase II clinical trial of imatinib mesylate for advanced gastrointestinal stromal tumors in Japan. Gann Mono Cancer Res
    268. (2007). Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest
    269. Prevalence and management of gastrointestinal stromal tumors.
    270. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    271. Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
    272. Prognosis and predictive value of KIT exon 11 deletion in GISTs.
    273. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours.
    274. (2003). Prognostic factors of toxicity and efficacy in patients with gastro-intestinal stromal tumors (GIST) treated with imatinib: a study of the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol
    275. (2008). Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg
    276. (2007). Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
    277. Proposals for the management of gastrointestinal stromal tumours of the stomach.
    278. (2008). Quality assessment at trial entry if study itself is randomised Quality criteria Study ID Blanke
    279. radiological and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate: a review of 37 cases.
    280. Recent developments in pharmacotherapy of cancer.
    281. (2005). Receptor tyrosine kinase activity and apoptosis in gastrointestinal stromal tumours: a pharmacodynamic analysis of response to sunitinib malate (SU11248) therapy. Clin Cancer Res
    282. Recurrence after imatinib treatment for patients with gastrointestinal stromal tumor.
    283. (2000). Recurrent gastrointestinal stromal sarcomas. Surg Oncol
    284. Relative hypocalcaemia and muscle cramps in patients receiving imatinib for gastrointestinal stromal tumour. Sarcoma 2006;2006:Article ID 48948. Imatinib dose not reported (n = 84) Al Batran
    285. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.
    286. (2009). Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment. doi
    287. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression.
    288. (2002). Response to imatinib mesylate (GleevecTM) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT. Radiology
    289. Results from a continuation trial of SU11248 in patients with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST).
    290. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
    291. (2006). Results of a singlecenter experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg
    292. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008;19:359–61. Raut
    293. Results of primary surgical treatment of gastrointestinal stromal tumors.
    294. (2007). Retrospective analysis of the use of imatinib mesylate in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST).
    295. (2007). Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol
    296. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients.
    297. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
    298. Safety and efficacy results of sunitinib from a worldwide treatment use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy.
    299. Safety and tolerability of sunitinib (SU) initiated 24 h after the last dose of imatinib (IM) in advanced GIST.
    300. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection.
    301. Scrotal cutaneous side effects of sunitinib.
    302. (2008). Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci
    303. Secondary resistance to imatinib in patients with gastrointestinal stromal tumors through an acquired KIT exon 17 mutation.
    304. (2003). Selective tyrosine kinase inhibitors: imatinib in GIST. Tumori
    305. (1991). Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg
    306. (2006). Size does not matter! Patterns of response and progression in patients (PTS) with metastatic gastrointestinal stromal tumours (GISTS) on imatinib mesylate (IM). Ann Oncol
    307. (2009). Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg
    308. Small bowel cancer: single-centre results over a period of 12 years.
    309. Small molecule therapy: overcoming imatinib resistance in gastrointestinal stromal tumors.
    310. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.
    311. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.
    312. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).
    313. Sunitinib (Su) in a worldwide treatment-use trial of patients with GIST: updated efficacy and safety analysis. Ann Oncol 2008;19(Suppl. 8):viii267-Abstract 869PD.
    314. Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: early results from a ‘treatment-use’ trial.
    315. Sunitinib in a worldwide treatment-use trial of patients with imatinib-resistant/intolerant gastrointestinal stromal tumor: detailed analysis of survival and safety. Ann Oncol 2008;19(Suppl. 6):vii12-Abstract O-013.
    316. Sunitinib in Japanese patients with GIST after prior treatment with imatinib mesylate: a phase I/II dose-escalation study.
    317. Sunitinib malate: oncolytic drug multitargeted tyrosine kinase inhibitor.
    318. (2007). Sunitinib treatment of GIST in Japanese patients after failure of prior imatinib treatment: a phase II trial. Ann Oncol
    319. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.
    320. (2004). Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev
    321. (2009). Surg Oncol
    322. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas.
    323. (2005). Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST).
    324. (2007). Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg
    325. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). doi
    326. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy.
    327. Surgical management and clinical outcome of gastro-intestinal stromal tumor of the colon and rectum.
    328. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
    329. (2007). Surgical outcomes and immunohistochemical features for gastrointestinal stromal tumors (GISTS) of the stomach: with special reference to prognostic factors. Hepatogastroenterology
    330. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination.
    331. Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy.
    332. Surgical pathology and outcome of gastrointestinal stromal tumors of the stomach. Gastroenterology 2004;126(Suppl. 2):61. Treatment not evaluated (n
    333. (2008). Surgical treatment for gastric GIST with special reference to liver metastases. Hepatogastroenterology
    334. (2003). Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery
    335. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    336. (2008). Survival from metastatic gastrointestinal stromal tumors in the era of imatinib. Ann Surg Oncol
    337. Targeted cancer therapies: herceptin and SUTENT.
    338. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). doi
    339. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
    340. (1998). The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus.
    341. (2001). The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg
    342. The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours.
    343. (1998). The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.
    344. (2007). The outcome of gastrointestinal stromal tumors (GISTs) after a surgical resection in our institute. Surg Today
    345. (2005). The outcomes of patients with metastatic/inoperable gastrointestinal stromal tumors (GIST) treated with imatinib: an interim multicenter analysis of Polish Clinical GIST Registry. Nowotwory
    346. The potential value of F-18 FDG PET in comparison to CT in early prediction of response to imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
    347. (2005). The radiology of gastrointestinal stromal tumours (GIST). Cancer Imaging
    348. The role of CT density measurement to monitor the gastrointestinal stromal tumors after treatment with STI571: a quantitative analysis.
    349. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. doi
    350. (2008). Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res
    351. (2006). TK-inhibitors in the clinical management of GIST. What’s up, what’s next? Supp Palliat Cancer Care
    352. (2011). Tolerance of imatinib mesylate in chronic myeloid leukemia and gastro intestinal stromal tumours patients: an experience from India. Ann Oncol
    353. (2005). Tolerance of imatinib mesylate in chronic myeloid leukemia and gastrointestinal stromal tumours patients: an experience from India. Ann Oncol
    354. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
    355. (2006). Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg. Dig Dis
    356. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib: and then?
    357. (2002). Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec,
    358. Trough imatinib plasma levels in patients treated for advanced gastrintestinal stromal tumors evidence of large interpatient variations under treatment with standard doses.
    359. Tumor response to imatinib mesylate in advanced GIST.
    360. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.
    361. (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg
    362. (2009). Unit costs of health and social care 2009. Canterbury: Personal Social Services Research Unit;
    363. (2007). Up to 6 years’ follow-up of patients receiving imatinib mesylate (Glivec) to treat unresectable or metastatic gastrointestinal stromal tumors (GISTs). doi
    364. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
    365. (2006). Updated results from a ‘treatment-use’ trial of sunitinib in advanced gastrointestinal stromal tumor (GIST). Ann Oncol
    366. (2011). Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance.
    367. (2007). updates. Sunitinib in the treatment of metastatic renal carcinoma and the gastrointestinal stromal tumors.
    368. US Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    369. Use of c-KIT/ PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. doi
    370. Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST).
    371. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
    372. (2008). Value of CT in the diagnosis and follow-up of gastrointestinal stromal tumors. Clin Imaging
    373. We should desist using RECIST, at least in GIST.
    374. Winbugs: a Bayesian modelling framework: concepts, structure, and extensibility.
    375. (2000). World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.